We have a robust competitive moat in a complex IP landscape. As one of the pioneers in this field, we have built one of the most robust intellectual property portfolios in nucleic acid-based technology worldwide. As of April 18, 2025, we had a total of 458 patents and patent applications globally, covering major jurisdictions such as China, Europe, the U.S. and Japan, including 229 granted patents and 229 pending applications, in relation to siRNA sequences, chemical modifications, delivery technologies, molecular structures, combination therapies and clinical applications, among others, to protect our technologies and drug assets. Our IP moat has solidified our leadership position in the industry and will continue to be a crucial factor to success.
We have developed RiboGalSTARTM, RiboOncoSTARTM，RiboPepSTARTM, dual-targeting and multi-targeting delivery technologies and RSC modification technologies, which we have filed patent applications for. Some of them have been granted patents in various jurisdictions like China, Europe and the U.S.
We also focus on R&D breakthroughs in dual-targeting and multi-targeting technologies, as well as advanced chemical modification and synthesis technologies. Our RSC (Ribo Stabilization Chemistry) technology platform, protected by patents in major markets including the U.S., Canada, and Australia, has evolved through multiple generations to optimize oligonucleotide therapeutics.
Our intellectual property portfolios also include trade secret, trademark as well as domain names.
